Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate
Other stock markets
 02:35:01 2024-05-29 am EDT 		5-day change 1st Jan Change
17.8 EUR -6.81% Intraday chart for Frazier Lifesciences Acquisition Corporation -1.95% +70.99%
May. 16 Transcript : NewAmsterdam Pharma Company N.V. - Special Call
May. 15 TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
AQ
Transcript : NewAmsterdam Pharma Company N.V. - Special Call
TD Cowen Starts NewAmsterdam Pharma With Buy Rating
MT
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
MT
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GL
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GL
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
CI
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer
MT
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
AQ
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
CI
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing
MT
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
GL
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. News Frazier Lifesciences Acquisition Corporation